Medcaptain 02041 Prospectus Information

IPO Timeline Raw facts

Broker Deadline

2026-09-02

Morning deadline

HKEX Deadline

2026-09-02

Noon deadline

Broker Results (T-2)

2026-09-03

Some brokers release in afternoon

Grey Market (T-1)

2026-09-04

Afternoon

HKEX Allotment (T-1)

2026-09-04

Evening

Registrar Allotment (T-1)

2026-09-04

Evening

Listing Day (T)

2026-09-07

First day of trading

Company Overview

Stock Name	Medcaptain
Stock Code	02041
Company Full Name	Medcaptain Medical Technology Co., Ltd.
Industry	Healthcare
Principal Activities	A global medical device provider, capable of meeting the clinical needs of a wide range of clinical departments, wards and clinics within medical institutions, as well as community health centers, testing institutions and home care settings.
Listing Date	2026-09-07
Listing Rules Era	New Rules (after Aug 2025)
Listing Rules Chapter	8A不同投票权
Weighted Voting Rights (WVR)	No
Registered Address (Mainland China)	深圳市南山區西麗打石一路深圳國際創新谷7棟A座701房
Business Address (Hong Kong)	香港銅鑼灣希慎道33號利園一期19樓1916室
Place of Incorporation	China
Listing Method	Global Offering
Listing Board	Main Board
Website	medcaptain.com
Share Registrar	卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact	卓佳证券登记有限公司，香港金钟道89号力宝中心1座31楼3101-3103室
A-Share/US Dual Listing	No

Offering Information

Offering Mechanism	Mechanism B
Offer Price	HK$ 15.42 / shares
Offer Price Range	Final offer price only, no range
Lot Size	100 shares
Entry Threshold	HK$ 1,542
Par Value	RMB 1.0 / shares
Offer Period	2026-08-28 to 2026-09-02
Global Offering Shares	38,910,600 shares
HK Public Offer Shares (Initial)	3,891,100 shares (10.0%)
Public Offer Lots (Initial)	38,911lots (19,455lots, 19,456lots)
International Placing Shares (Initial)	35,019,500 shares (90.0%)
Offer Ratio	~10.0%
Total Shares Post-IPO	538,626,686 shares
Greenshoe (Over-allotment Option)	No
Stabilizing Manager (Greenshoe)	—
Cornerstone Share	No cornerstone investors
Clawback Tiers	Mechanism B: no clawback mechanism
Reallocation Option	Yes
Total Global Offering Size	HK$ 600,001,452

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A

Lots Subscribed	Shares Subscribed	Subscription Amount (HKD)
1 lots	100	HK$ 1,542
2 lots	200	HK$ 3,084
3 lots	300	HK$ 4,626
4 lots	400	HK$ 6,168
5 lots	500	HK$ 7,710
6 lots	600	HK$ 9,252
7 lots	700	HK$ 10,794
8 lots	800	HK$ 12,336
9 lots	900	HK$ 13,878
10 lots	1,000	HK$ 15,420
15 lots	1,500	HK$ 23,130
20 lots	2,000	HK$ 30,840
25 lots	2,500	HK$ 38,550
30 lots	3,000	HK$ 46,260
35 lots	3,500	HK$ 53,970
40 lots	4,000	HK$ 61,680
45 lots	4,500	HK$ 69,390
50 lots	5,000	HK$ 77,100
60 lots	6,000	HK$ 92,520
70 lots	7,000	HK$ 107,940
80 lots	8,000	HK$ 123,360
90 lots	9,000	HK$ 138,780
100 lots	10,000	HK$ 154,200
200 lots	20,000	HK$ 308,400
300 lots	30,000	HK$ 462,600
400 lots	40,000	HK$ 616,800
500 lots	50,000	HK$ 771,000
600 lots	60,000	HK$ 925,200
700 lots	70,000	HK$ 1,079,400
800 lots	80,000	HK$ 1,233,600
900 lots	90,000	HK$ 1,387,800
1,000 lots	100,000	HK$ 1,542,000
2,000 lots	200,000	HK$ 3,084,000
3,000 lots	300,000	HK$ 4,626,000

Pool B

Lots Subscribed	Shares Subscribed	Subscription Amount (HKD)
4,000 lots	400,000	HK$ 6,168,000
5,000 lots	500,000	HK$ 7,710,000
6,000 lots	600,000	HK$ 9,252,000
7,000 lots	700,000	HK$ 10,794,000
8,000 lots	800,000	HK$ 12,336,000
9,000 lots	900,000	HK$ 13,878,000
10,000 lots	1,000,000	HK$ 15,420,000
15,000 lots	1,500,000	HK$ 23,130,000
19,455 lots	1,945,500	HK$ 29,999,610

Stock Connect Inclusion

HK Market Cap	HK$ 3.54B

26Q3 Fast Review
Inclusion Pathway	Quarterly Fast Inclusion
Est. Threshold	HK$ 19.28B Market cap gap 81%
Analysis Result	Market cap below threshold (gap 81%)

26Q4 Regular Review
Inclusion Pathway	Small Cap Regular Path
Est. Threshold	HK$ 9.56B Market cap gap 63%
Analysis Result	Market cap below threshold (gap 63%)

Valuation & Financials

Market Cap (at Offer Price)	HK$ 8,305,623,498
H-Share Market Cap (at Offer Price)	HK$ 7,389,598,398
Pre-IPO Valuation (Last Round)	Not disclosed
P/E Ratio	Not disclosed
Profit/Loss Status	Net profit RMB 50.7 million
Period-End Cash Balance	RMB 301.26 million
Listing Expenses	To be extracted
Listing Expenses / Funds Raised	To be extracted
Total Pre-IPO Investment	approximately RMB 359.8 million

First Day Performance

First Day Close	Loading...

Use of Proceeds

Use of Proceeds	Approximately 35.0% for research and development, approximately 20.0% for developing manufacturing centers to expand production capacity, approximately 20.0% for enhancing sales and marketing capabilities, approximately 10.0% for potential strategic investments and acquisitions, approximately 5.0% for upgrading IT infrastructure and digital platforms, and approximately 10.0% for working capital and other general corporate purposes.

Approximately 35.0% for research and development, approximately 20.0% for developing manufacturing centers to expand production capacity, approximately 20.0% for enhancing sales and marketing capabilities, approximately 10.0% for potential strategic investments and acquisitions, approximately 5.0% for upgrading IT infrastructure and digital platforms, and approximately 10.0% for working capital and other general corporate purposes.

Underwriting Syndicate

Joint Sponsors (1)

Morgan Stanley Asia Limited CE AAD291

Sponsor cum Overall Coordinator (1)

Morgan Stanley Asia Limited CE AAD291

Overall Coordinators (2)

Morgan Stanley Asia Limited CE AAD291 Huatai Financial Holdings (Hong Kong) Limited CE AOK809

Joint Global Coordinators (3)

Morgan Stanley Asia Limited CE AAD291 Huatai Financial Holdings (Hong Kong) Limited CE AOK809 BNP PARIBAS SECURITIES (ASIA) LIMITED CE AAF669

Joint Bookrunners (12)

Morgan Stanley Asia Limited CE AAD291 Huatai Financial Holdings (Hong Kong) Limited CE AOK809 BNP PARIBAS SECURITIES (ASIA) LIMITED CE AAF669 CELESTIAL SECURITIES LIMITED CE AAF532 Eddid Securities and Futures Limited CE BHT550 Futu Securities International (Hong Kong) Limited CE AZT137 Huafu International Securities Limited CE BQC241 JINLUO SECURITIES LIMITED CE BOK354 SBI China Capital Financial Services Limited CE ABD523 TradeGo Markets Limited CE BRO637 UOB KAY HIAN (HONG KONG) LIMITED CE AAW261 Yuet Sheung International Securities Limited CE BEZ371

Joint Lead Managers (12)

Capital Market Intermediaries (12)

Service Providers

Role	Institution
Legal Advisor to Company	史密夫斐尔凯迈律师事务所 Jia Yuan Law Offices Hogan Lovells Cadwalader International LLP (formerly Hogan Lovells)
Legal Advisor to Sponsors/Underwriters	美迈斯律师事务所 Jingtian & Gongcheng
Auditor and Reporting Accountant	Ernst & Young
Industry Advisor	灼识行业咨询有限公司
Compliance Advisor	UOB KAY HIAN (HONG KONG) LIMITED CE AAW261
Receiving Banks	Bank of China (Hong Kong) Limited

Cornerstone Investors

This stock has no cornerstone investors.

Directors & Management

Chairman	LIU Jie
Company Secretary	顏仁仲

No director data available.

Major Shareholders

Major Shareholders & Holdings	Mr. Liu, Ms. Li and Mr. Zhong are the controlling shareholders, collectively controlling approximately 36.70% of the voting rights; other major shareholders include Zhuhai Hillhouse Fund Management, Shenzhen Innovation Investment Group, and others.

Medcaptain 02041Prospectus Information